ReviewDermatologie (Heidelberg, Germany)2026
[Chronic prurigo: overview of pathophysiology, diagnosis, and treatment].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic prurigo (CPG) remains a challenging disease. Besides diagnosis, which mostly relies on the S2k-guideline diagnosis and treatment of chronic pruritus, two systemic agents have been approved for the treatment of CPG in recent years.
objectivesThis review aims to provide an overview of the pathophysiology and current diagnostic and therapeutic recommendations for CPG. MATERIALS AND
methodsFor this review, a literature and clinical trial search was conducted via PubMed and Clinical Trials using the terms 'chronic prurigo', 'prurigo nodularis', 'pathophysiology', 'diagnosis', 'treatment' and 'therapy'. RESULTS AND
conclusionThe pathophysiology of CPG is becoming increasingly well understood. Building on this, a second targeted therapy for patients with moderate to severe CPG has recently been approved. Numerous other substances are currently undergoing clinical trials, offering the prospect of further improvements in the care of patients affected by CPG.
Indexed as
Identifiers
42228089What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.